Blockchain Registration Transaction Record

Lexaria Extends Pharma Deal for GLP-1 Drug Delivery Tech

Lexaria Bioscience extends Material Transfer Agreement with PharmaCO through 2026, advancing GLP-1 drug delivery technology. DehydraTECH platform shows promise for oral delivery of metabolic drugs.

This extension signals that a major pharmaceutical company sees promise in Lexaria's DehydraTECH platform for improving oral delivery of GLP-1 drugs. If successful, this technology could make diabetes and obesity treatments more effective and convenient, potentially benefiting millions of patients who rely on injectable therapies. It also highlights the growing importance of drug delivery innovation in addressing chronic diseases.